Literature DB >> 18214559

High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia.

M Sharma1, K Riederer, P Chase, R Khatib.   

Abstract

Daptomycin is bactericidal against Staphylococcus aureus, with susceptibility defined as a minimal inhibitory concentration (MIC) < or =1 microg/ml. Higher MIC developed in a few cases during therapy. The frequency of MIC rise in persistent bacteremia is unknown. We evaluated all patients with S. aureus bacteremia (SAB) treated with daptomycin (> or =2 days) from 1 April 2004 to 30 October 2006. All patients with post-daptomycin-exposure saved isolates were studied. Daptomycin susceptibility was determined (in duplicate) on all pre- and post-daptomycin-exposure isolates by the broth (Mueller-Hinton) microdilution method. Among 74 treatment courses in 67 patients, 18 were for SAB. Ten had persistent bacteremia (median = 11 days; range = 1-21) and post-daptomycin-exposure saved isolates. The patient age was 29-84 years (median = 57.5 years). Intravascular catheter was the most common source (50%). Most patients (90%) failed therapy prior to starting daptomycin. The initial daptomycin dose was 4 mg/kg in four (40%) cases. The pre-exposure MIC was 0.125-0.5 microg/ml. The post-exposure MIC increased in four cases and was elevated in two cases (60%), to 2 microg/ml in five and 4 microg/ml in one. MIC rise was noted within 5-15 days of exposure and persisted up to 247 days after stopping daptomycin. Pulse-field gel electrophoresis (PFGE) band pattern of isolates with increased MIC revealed 1-3-band differences, implying genetic relatedness. All patients with non-susceptible isolates relapsed or failed therapy. These findings illustrate that daptomycin susceptibility often decreases during the treatment of persistent SAB. Therefore, susceptibility should be closely monitored during therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18214559     DOI: 10.1007/s10096-007-0455-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus.

Authors:  Jean B Patel; Laura A Jevitt; Jeffery Hageman; L Clifford McDonald; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2006-06-01       Impact factor: 9.079

3.  Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.

Authors:  M K Hayden; K Rezai; R A Hayes; K Lolans; J P Quinn; R A Weinstein
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

Review 5.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

6.  Mechanisms of daptomycin resistance in Staphylococcus aureus.

Authors:  Glenn W Kaatz; Tammy S Lundstrom; Susan M Seo
Journal:  Int J Antimicrob Agents       Date:  2006-09-11       Impact factor: 5.283

7.  Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  A Mangili; I Bica; D R Snydman; D H Hamer
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

8.  Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.

Authors:  Daniel J Skiest
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

9.  Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Authors:  Francisco M Marty; Wendy W Yeh; Christine B Wennersten; Lata Venkataraman; Esperanza Albano; Edwin P Alyea; Howard S Gold; Lindsey R Baden; Satish K Pillai
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

10.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more
  34 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Impact of Bacterial Membrane Fatty Acid Composition on the Failure of Daptomycin To Kill Staphylococcus aureus.

Authors:  Rym Boudjemaa; Clément Cabriel; Florence Dubois-Brissonnet; Nicolas Bourg; Guillaume Dupuis; Alexandra Gruss; Sandrine Lévêque-Fort; Romain Briandet; Marie-Pierre Fontaine-Aupart; Karine Steenkeste
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Discovery and Development of 8-Substituted Cycloberberine Derivatives as Novel Antibacterial Agents against MRSA.

Authors:  Tianyun Fan; Xinxin Hu; Sheng Tang; Xiaojia Liu; Yanxiang Wang; Hongbin Deng; Xuefu You; Jiandong Jiang; Yinghong Li; Danqing Song
Journal:  ACS Med Chem Lett       Date:  2018-04-16       Impact factor: 4.345

4.  Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients.

Authors:  Matteo Bassetti; Giovanni Villa; Filippo Ansaldi; Daniela De Florentiis; Carlo Tascini; Piergiogio Cojutti; Elda Righi; Assunta Sartor; Massimo Crapis; Francesco Giuseppe De Rosa; Federico Pea; Francesco Menichetti
Journal:  Intensive Care Med       Date:  2014-12-02       Impact factor: 17.440

5.  A Tick Antivirulence Protein Potentiates Antibiotics against Staphylococcus aureus.

Authors:  Nabil M Abraham; Lei Liu; Brandon L Jutras; Kristen Murfin; Ali Acar; Timur O Yarovinsky; Erica Sutton; Martin Heisig; Christine Jacobs-Wagner; Erol Fikrig
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 6.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

8.  Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE).

Authors:  B A Cunha; F M Pherez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-28       Impact factor: 3.267

Review 9.  Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit.

Authors:  Lee P Skrupky; Scott T Micek; Marin H Kollef
Journal:  Crit Care       Date:  2009-10-08       Impact factor: 9.097

10.  In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.

Authors:  Alexander J Lepak; Ajit Parhi; Michaela Madison; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.